Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Agile Therapeutics Inc    AGRX

AGILE THERAPEUTICS INC (AGRX)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/13/2018 07/16/2018 07/17/2018 07/18/2018 07/19/2018 Date
0.5399(c) 0.5119(c) 0.4843(c) 0.515(c) 0.51(c) Last
192 309 195 795 599 305 1 456 395 441 063 Volume
-2.01% -5.19% -5.39% +6.34% -0.97% Change
More quotes
Financials (USD)
Sales 2018 -
EBIT 2018 -25,2 M
Net income 2018 -25,6 M
Debt 2018 -
Yield 2018 -
Sales 2019 10,6 M
EBIT 2019 -40,7 M
Net income 2019 -41,4 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0
Capi. / Sales2019 1,56x
Capitalization 16,6 M
More Financials
Company
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch for use in contraception.It offers its product candidate Twirla, which is an investigational non-daily prescription contraceptive.The company was founded by Chien Te Yen on... 
More about the company
Surperformance© ratings of Agile Therapeutics Inc
Trading Rating : Investor Rating : -
More Ratings
Latest news on AGILE THERAPEUTICS INC
07/09AGILE THERAPEUTICS INC : Notice of Delisting or Failure to Satisfy a Continued L..
AQ
06/25Free Technical Research on Akorn and Three More Generic Drugs Equities
AC
06/21AGILE THERAPEUTICS INC : Change in Directors or Principal Officers (form 8-K)
AQ
06/08AGILE THERAPEUTICS : Provides Corporate Update and Revised Cash Guidance
AQ
06/07AGILE THERAPEUTICS INC : Submission of Matters to a Vote of Security Holders, Ot..
AQ
06/07AGILE THERAPEUTICS : Provides Corporate Update and Revised Cash Guidance
AQ
05/25AGILE THERAPEUTICS : Patent Application Titled "Contraceptive Compositions and M..
AQ
05/22AGILE THERAPEUTICS : Provides Regulatory Update on Twirla for the Prevention of ..
AQ
05/21AGILE THERAPEUTICS INC : Today’s Research Reports on Stocks to Watch: Agile Ther..
AC
05/18AGILE THERAPEUTICS INC : Other Events, Financial Statements and Exhibits (form 8..
AQ
More news
Sector news : Bio Therapeutic Drugs
07/19Novartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
07/18Agile Therapeutics $AGRX Trading Down 5.9%  
07/17Reviewing Chiasma $CHMA and Agile Therapeutics $AGRX  
07/07Get the latest ratings for $AGRX $MGEN $EPC $CFRX $HSKA in your inbox with Ma..
1
07/06Analysts Set Agile Therapeutics Inc $AGRX Price Target at $4.00  
07/06ValuEngine Downgrades Agile Therapeutics $AGRX to Sell  
More tweets
Qtime:326
News from SeekingAlpha
06/15An Update On Corium International 
05/24INSTITUTIONAL TOP IDEAS SERIES : Perceptive Advisors 
05/21Agile Therapeutics Is Attempting A Hail Mary Play With A Formal Dispute Resol.. 
05/21YOUR DAILY PHARMA SCOOP : Abeona Presents Strong Data, Glaxo Nucala Treatment Be.. 
05/18Midday Gainers / Losers (05/18/2018) 
Chart AGILE THERAPEUTICS INC
Duration : Period :
Agile Therapeutics Inc Technical Analysis Chart | AGRX | US00847L1008 | 4-Traders
Technical analysis trends AGILE THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 6,00 $
Spread / Average Target 1 065%
EPS Revisions
Managers
NameTitle
Alfred F. Altomari Chairman & Chief Executive Officer
Scott M. Coiante Senior VP, Chief Financial & Accounting Officer
Elizabeth Ijeoma Onyemelukwe Garner Chief Medical Officer & Senior Vice President
Abhijeet J. Lele Lead Independent Director
William T. McKee Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AGILE THERAPEUTICS INC-81.04%17
GILEAD SCIENCES7.65%100 380
VERTEX PHARMACEUTICALS20.87%46 529
REGENERON PHARMACEUTICALS-2.65%38 717
GENMAB9.57%10 693
NEUROCRINE BIOSCIENCES, INC.33.03%9 398